December 2017 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2015/16 Invitation to Tender, dated 6 November 2015 and the 2016/17 Invitation to Tender, dated 3 November 2016.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (http://www.pgnz.org.nz/pharmacode) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (http://www.nzulm.org.nz/sponsors(external link)). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2015/16 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2019
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy (and price) | New subsidy (and price) | Sole supply brand (Supplier) |
Date of subsidy change | Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
| Tamsulosin hydrochloride | Cap 400 mcg, 100 cap blister pack* |
$13.51 | $11.25 | Tamsulosin-Rex (Rex Medical Ltd) |
1 July 2018 | 1 October 2018 |
* Note: Tamsulosin hydrochloride was initially notified in error as a bottle pack instead of the correct blister pack.
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy (and price) | New subsidy (and price) | Sole supply brand (Supplier) |
Date of subsidy change | Hospital Supply Status date |
|---|---|---|---|---|---|---|
| Tamsulosin hydrochloride | Cap 400 mcg, 100 cap blister pack* |
$13.51 | $11.25 | Tamsulosin-Rex (Rex Medical Ltd) |
1 July 2018 | 1 September 2018 |
* Note: Tamsulosin hydrochloride was initially notified in error as a bottle pack instead of the correct blister pack.
2016/17 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2020
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
3. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Lamivudine | Tab 100 mg, 28 bottle pack |
$6.00 | $4.20 | Zetlam (Mylan) |
1 May 2018 | 1 July 2018 | 1 October 2018 | Zeffix (GSK) |
| Thiamine hydrochloride | Tab 50 mg, 100 tablet, bottle pack |
$5.62 | $4.89 | Max Health (Max Health) |
1 September 2018 | 1 November 2018 | 1 February 2019 | Apo-Thiamine (Apotex) |
| Zinc and castor oil* | Oint 500 g, tub 500 g |
$5.95 | $4.25 | Boucher (Boucher and Muir NZ Limited) |
1 May 2018 | 1 July 2018 | 1 October 2018 | Multichem (Multichem) |
| Chemical name | Presentation; Pack size and type |
Current pack price |
New pack price |
Sole Supply Brand (Supplier) |
Date of listing/ subsidy change for tender winning brand |
Date of reference pricing of other listed brands |
Sole Subsidised Supply date (and delisting of other listed brands) |
Brand (Supplier) affected by reference pricing and delisting |
|---|
* Note presentation description change from zinc and castor oil oint BP to zinc and castor oil oint from 1 February 2018.
4. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy (and price) | New subsidy (and price) | Sole supply brand (Supplier) |
Date of subsidy change | Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
| Ondansetron | Tab disp 4 mg, 10 blister pack |
$1.00 | $0.95 | Ondansetron ODT-DRLA* (Dr Reddy’s) |
1 February 2018 | 1 May 2018 |
| Tab disp 8 mg, 10 blister pack |
$1.50 | $1.43 | Ondansetron ODT-DRLA (Dr Reddy’s) |
1 February 2018 | 1 May 2018 |
* Note brand name change from Dr Reddy’s Ondansetron to Ondansetron ODT-DRLA from 1 February 2018.
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
5. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Lamivudine | Tab 100 mg, 28 bottle pack |
$6.00 | $4.20 | Zetlam (Mylan New Zealand Ltd) |
1% | 1 May 2018 | 1 July 2018 | Zeffix (GSK) |
| Chemical name | Presentation; Pack size and type |
Current pack price |
New pack price |
Hospital Supply Brand (Supplier) |
DV Limit | Listing date | Hospital Supply Status date | Brand (Supplier) affected by delisting |
|---|
6. Tenders awarded to listed pharmaceuticals where no brand is listed
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Pack price |
Hospital Supply Brand (Supplier) | DV Limit | Listing date | Hospital Supply Status date |
|---|---|---|---|---|---|---|
| Thiamine hydrochloride | Tab 50 mg, 100 tablet, bottle pack |
$4.89 | Max Health (Max Health) |
1% | 1 September 2018 | 1 November 2018 |
| Zinc and castor oil | Oint, tub 500 g | $4.25 | Boucher (Boucher and Muir NZ Limited) |
1% | 1 May 2018 | 1 July 2018 |
7. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy (and price) | New subsidy (and price) | Sole supply brand (Supplier) |
DV Limit | Date of subsidy change | Sole Subsidised Supply date |
|---|---|---|---|---|---|---|---|
| Ondansetron | Tab disp 4 mg, 10 blister pack |
$1.00 | $0.95 | Ondansetron ODT-DRLA* (Dr Reddy’s) |
1% | 1 February 2018 | 1 April 2018 |
| Tab disp 8 mg, 10 blister pack | $1.50 | $1.43 | Ondansetron ODT-DRLA (Dr Reddy’s) |
1% | 1 February 2018 | 1 April 2018 |
* Note brand name change from Dr Reddy’s Ondansetron to Ondansetron ODT-DRLA from 1 February 2018.
Tender declines – Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2016/17 Invitation to Tender dated 3 November 2016.
| Chemical name | Line item |
|---|---|
| Albendazole | Tab 200 mg |
| Lamivudine | Oral liq 5 mg per mL |
| Zinc and castor oil | Oint BP (pack size greater than 30 g) |
| Zolmitriptan | Nasal spray |
For products included in the 2015/16 and 2016/17 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.